Identifying <font color="red">patients_4</font> <font color="red">at_4</font> <font color="red">high_4</font> <font color="red">risk_4</font> <font color="red">for_4</font> <font color="red">neutropenic_4</font> <font color="red">complications_4</font> <font color="red">during_2</font> <font color="red">chemotherapy_2</font> <font color="red">for_2</font> <font color="red">metastatic_2</font> <font color="red">breast_2</font> <font color="red">cancer_2</font> <font color="red">with_1</font> <font color="red">doxorubicin_1</font> <font color="red">or_1</font> <font color="red">pegylated_1</font> <font color="red">liposomal_1</font> <font color="red">doxorubicin_1</font> <font color="red">:_1</font> the development of a prediction model . 
<br>
<br> OBJECTIVE <font color="red">To_1</font> <font color="red">develop_1</font> <font color="red">a_1</font> <font color="red">cycle_1</font> <font color="red">-_1</font> <font color="red">based_1</font> <font color="red">risk_1</font> <font color="red">prediction_1</font> <font color="red">model_1</font> <font color="red">for_1</font> <font color="red">neutropenic_1</font> <font color="red">complications_1</font> <font color="red">(_1</font> <font color="red">NC_1</font> <font color="red">)_1</font> <font color="red">during_1</font> <font color="red">chemotherapy_1</font> <font color="red">with_1</font> <font color="red">doxorubicin_1</font> <font color="red">(_1</font> <font color="red">DOX_1</font> <font color="red">)_1</font> <font color="red">or_1</font> <font color="red">a_1</font> <font color="red">pegylated_1</font> <font color="red">liposomal_1</font> <font color="red">formulation_1</font> <font color="red">(_1</font> <font color="red">PLD_1</font> <font color="red">)_1</font> <font color="red">for_1</font> <font color="red">patients_5</font> <font color="red">with_5</font> <font color="red">metastatic_5</font> <font color="red">breast_5</font> <font color="red">cancer_5</font> <font color="red">(_5</font> <font color="red">MBC_5</font> <font color="red">)_5</font> <font color="red">._4</font> <font color="red">
<br>_1</font> <font color="red">METHODS_1</font> <font color="red">Data_1</font> <font color="red">analyzed_1</font> <font color="red">was_1</font> <font color="red">from_1</font> <font color="red">a_1</font> <font color="red">phase_1</font> <font color="red">III_1</font> <font color="red">,_1</font> <font color="red">randomized_1</font> <font color="red">clinical_1</font> <font color="red">trial_1</font> <font color="red">of_1</font> <font color="red">DOX_1</font> <font color="red">(_1</font> <font color="red">60_1</font> <font color="red">mg_1</font> <font color="red">/_1</font> <font color="red">m(2_1</font> <font color="red">)_1</font> <font color="red">every_1</font> <font color="red">3_1</font> <font color="red">weeks_1</font> <font color="red">)_1</font> <font color="red">or_1</font> <font color="red">PLD_1</font> <font color="red">(_1</font> <font color="red">50_1</font> <font color="red">mg_1</font> <font color="red">/_1</font> <font color="red">m(2_1</font> <font color="red">)_1</font> <font color="red">every_1</font> <font color="red">4_1</font> <font color="red">weeks_1</font> <font color="red">)_1</font> <font color="red">for_1</font> <font color="red">the_1</font> <font color="red">first_1</font> <font color="red">line_1</font> <font color="red">therapy_1</font> <font color="red">for_1</font> <font color="red">MBC_1</font> <font color="red">(_1</font> <font color="red">n_2</font> <font color="red">=_2</font> <font color="red">509_2</font> <font color="red">)_2</font> <font color="red">(_1</font> <font color="red">O'Brien_1</font> <font color="red">et_1</font> <font color="red">al_1</font> <font color="red">,_1</font> <font color="red">Ann_1</font> <font color="red">Oncol_1</font> <font color="red">._1</font> <font color="red">2004;15:440_1</font> <font color="red">-_1</font> <font color="red">449_1</font> <font color="red">)_1</font> <font color="red">._1</font> <font color="red">NC_1</font> <font color="red">were_1</font> <font color="red">defined_1</font> <font color="red">as_1</font> <font color="red">an_1</font> <font color="red">absolute_1</font> <font color="red">neutrophil_1</font> <font color="red">count_1</font> <font color="red"><_1</font> <font color="red">or_1</font> <font color="red">=_1</font> <font color="red">1.5_1</font> <font color="red">x_1</font> <font color="red">10(9_1</font> <font color="red">)_1</font> <font color="red">cells_1</font> <font color="red">/_1</font> <font color="red">L_1</font> <font color="red">(_1</font> <font color="red">ie_1</font> <font color="red">,_1</font> <font color="red">>_1</font> <font color="red">or_1</font> <font color="red">=_1</font> <font color="red">grade_1</font> <font color="red">II_1</font> <font color="red">)_1</font> <font color="red">before_1</font> <font color="red">the_1</font> <font color="red">next_1</font> <font color="red">cycle_1</font> <font color="red">,_1</font> <font color="red">febrile_1</font> <font color="red">neutropenia_1</font> <font color="red">or_1</font> <font color="red">neutropenia_1</font> <font color="red">with_1</font> <font color="red">a_1</font> <font color="red">documented_1</font> <font color="red">infection_1</font> <font color="red">._1</font> <font color="red">Patient_2</font> <font color="red">and_1</font> <font color="red">hematologic_1</font> <font color="red">factors_1</font> <font color="red">potentially_1</font> <font color="red">associated_1</font> <font color="red">with_1</font> <font color="red">NC_1</font> <font color="red">were_1</font> <font color="red">evaluated_1</font> <font color="red">._1</font> Factors with a P value of < or = 0.25 within a cycle were included in a generalized estimating equations regression model . Using backward elimination , we derived a risk scoring algorithm ( range 0 - 63 ) from the final reduced model . 
<br> RESULTS Risk factors retained in the model included poor performance status , absolute neutrophil count < or = 2.0 x 10(9 ) cells / L in the previous cycle , the first cycle of chemotherapy , DOX versus PLD and advanced age . A precycle risk score from > or = 25 to < 40 for a given <font color="red">patient_1</font> was identified as being the optimal threshold for sensitivity ( 58.0% ) and specificity ( 78.7% ) . <font color="red">Patients_1</font> with a score at or beyond this threshold would be considered at high risk for developing NC in later cycles . 
<br> CONCLUSION The use of this model may enhance <font color="red">patient_1</font> care by targeting preventative therapies ( eg , granulocyte colony stimulating factor or PLD ) to those <font color="red">MBC_1</font> <font color="red">patients_2</font> most likely to experience NC during anthracycline - based chemotherapy .